Brexpiprazole
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Brexpiprazole |
| DrugBank ID | DB09128 |
| Brand Names (EU) | Rxulti |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.87% |
Approved Indication (EMA)
Rxulti is indicated for the treatment of schizophrenia in adult and adolescents aged 13 years and older.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | anxiety disorder | 98.87% | DL |
| 2 | dysthymic disorder | 98.53% | DL |
| 3 | benign paroxysmal torticollis of infancy | 98.30% | DL |
| 4 | agoraphobia | 98.23% | DL |
| 5 | neurotic disorder | 97.73% | DL |
| 6 | neurotic depression | 97.11% | DL |
| 7 | melancholia | 97.07% | DL |
| 8 | endogenous depression | 96.14% | DL |
| 9 | Keppen-Lubinsky syndrome | 96.05% | DL |
| 10 | schizophrenia | 96.03% | DL |
| 11 | Ohdo syndrome and variants | 94.97% | DL |
| 12 | retinal dystrophy with or without extraocular anomalies | 94.75% | DL |
| 13 | congenital isolated adrenocorticotropic hormone deficiency (disease) | 94.50% | DL |
| 14 | vitamin B12-responsive methylmalonic acidemia | 94.30% | DL |
| 15 | autosomal dominant slowed nerve conduction velocity | 94.01% | DL |
| 16 | major depressive disorder | 94.00% | DL |
| 17 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 93.95% | DL |
| 18 | hydranencephaly (disease) | 93.62% | DL |
| 19 | syndromic myopia | 93.58% | DL |
| 20 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 93.49% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.